| CTNT 0.1608 -5.80% | ZSPC 0.0871 21.48% | ONFO 1.5 124.89% | MYSE 3.3 129.17% | NVDA 198.35 -0.26% | BITO 10.35 0.49% | TZA 5.43 -0.46% | TSLL 13.07 -1.73% | INTC 68.5 5.48% | CAPS 0.5345 -9.25% | HUBC 0.1833 -29.50% | DVLT 0.8375 19.63% | SOXS 20.28 -3.13% | TQQQ 56.43 1.40% | QBTS 21.505 3.34% | AGAE 0.5219 10.57% | HIMS 26.99 11.12% | IONQ 44.68 3.31% | DGNX 0.5556 -0.79% | GRAB 4.02 2.55% | SNAP 6.02 -0.33% | SOFI 19.03 1.28% | SMR 11.41 -2.56% | TSLA 388.9 -0.78% | ITP 0.2 -3.57% | BMNG 1.53 0.66% | SOXL 88.37 2.80% | AMD 278.26 7.80% | RGTI 19.45 1.78% | OPEN 5.27 9.34% | MDCX 0.3003 -0.60% | PLUG 2.86 -2.39% | MARA 11.55 10.32% | NVD 5.81 0.69% | AAL 12.27 0.82% | SQQQ 58.61 -1.40% | IMMP 0.5796 6.54% | HOOD 86.85 -0.54% | ONDS 10.2 1.69% | NVTS 12.37 20.57% | RMSG 2.55 42.46% | BYND 0.782 4.11% | NOK 10.29 3.00% | NFLX 107.79 0.07% | ORCL 178.46 5.09% | SPY 701.66 0.25% | SOUN 7.7 -1.91% | AAPL 263.4 -1.14% | PBM 5.87 103.82% | PLTR 142.76 0.43%

Surgery Partners, Inc. (NASDAQ: SGRY) Faces Challenges but Shows Potential for Recovery

Surgery Partners, Inc. (NASDAQ: SGRY) is a healthcare services company that operates surgical facilities across the United States. The company provides a range of surgical services, including orthopedics, pain management, and ophthalmology. SGRY competes with other healthcare service providers like Tenet Healthcare and HCA Healthcare.
 
On March 3, 2026, amid the post-earnings reaction, the stock traded around $13.41 during the session. Despite the market reaction, SGRY’s stock price recently hit a 52-week low during a premarket session. This decline followed the release of disappointing fourth-quarter results and a cautious outlook for 2026. The company reported adjusted earnings of 12 cents per share, missing the expected 30 cents. This shortfall contributed to the stock’s decrease of approximately 12.91%, with a change of $2.05, bringing the price to $13.83 at one point during the session. However, not all news was negative for SGRY.
 
The company reported a 2.4% increase in sales year over year, reaching $885 million, which surpassed the consensus estimate of $866.47 million. Same-facility revenues for the fourth quarter of 2025 also saw a 3.5% increase, with revenue per case rising by 2.1% and same-facility cases increasing by 1.3%. These figures indicate some positive operational performance despite the overall challenges. The adjusted EBITDA for the fourth quarter was $156.9 million, down from $163.8 million the previous year. Additionally, cash flows from operating activities decreased to $103.4 million, compared to $111.4 million in the fourth quarter of 2024.
 
CEO Eric Evans acknowledged significant and unanticipated headwinds faced by the company, which contributed to the cautious outlook for 2026. SGRY’s market capitalization is approximately $1.79 billion, with a trading volume of 4,007,837 shares. The stock has fluctuated between a low of $12.25 and a high of $13.83 today, with a 52-week high of $24.64. Despite recent setbacks, the consensus analyst price target suggests potential for recovery and growth in the future.
Published on: March 3, 2026